Form 4 for BBIO BridgeBio Pharma, Inc.

Accepted 2026-07-13 16:41:33 ET · period of report 2026-07-09 · accession 0001470831-26-000709 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DT	2026-07-13 16:41	2026-07-09	BBIO	Ellis Andrea	Dir	M - OptEx	$16.75	+17.2K	39.7K	+76%	+$287.5K
DT	2026-07-13 16:41	2026-07-09	BBIO	Ellis Andrea	Dir	S - Sale+OE	$84.00	-17.2K	22.6K	-43%	-$1.44M
DT	2026-07-13 16:41	2026-07-09	BBIO	Ellis Andrea	Dir	M - OptEx	$0.00	-17.2K	17.2K	-50%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-07-09	M	A	17,167	$16.75	39,746	D	—	—	(F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025.
2	Common	Common Stock	2026-07-09	S	D	17,167	$84.00	22,579	D	—	—	(F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025.
3	Derivative	Stock Option (right to buy)	2026-07-09	M	D	17,167	$0.00	17,167	D	$16.75 · — to 2033-06-21	17,167 Common Stock	(F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025. (F2) 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.